Literature DB >> 19414240

Resistance to macrolides by ribosomal mutation in clinical isolates of Turicella otitidis.

Leyla Boumghar-Bourtchai1, Hubert Chardon, Brigitte Malbruny, Senda Mezghani, Roland Leclercq, Anne Dhalluin.   

Abstract

The genetic basis of erythromycin resistance in Turicella otitidis, a coryneform bacteria associated with otitis, was studied in five macrolide-resistant clinical isolates. Macrolide resistance genes were searched for by polymerase chain reaction (PCR). Genes for domain V of 23S rRNA (rrl) as well as rplD (L4 protein) and rplV (L22 protein) genes were characterised, amplified by PCR from total genomic DNA and sequenced. In the resistant isolates, cross-resistance to macrolides and clindamycin was associated with mutations at positions 2058 and/or 2059 (Escherichia coli numbering). Three isolates displayed A2058 mutations, one isolate had an A2059G mutation whereas another one contained mutations at positions 2058 and 2059. Southern blot experiments revealed that T. otitidis had three copies of the rrl gene. In conclusion, resistance to macrolides in T. otitidis is due, at least in part, to mutations in the rrl gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414240     DOI: 10.1016/j.ijantimicag.2009.03.023

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

Review 1.  Turicella otitidis and Corynebacterium auris: 20 years on.

Authors:  A von Graevenitz; G Funke
Journal:  Infection       Date:  2013-06-18       Impact factor: 3.553

2.  Draft Genome Sequence of Turicella otitidis TD1, Isolated from a Patient with Bacteremia.

Authors:  Alexander L Greninger; Varvara Kozyreva; Chau-Linda Truong; Margot Graves; Vishnu Chaturvedi
Journal:  Genome Announc       Date:  2015-09-17

Review 3.  Reviewing the Pathogenic Potential of the Otitis-Associated Bacteria Alloiococcus otitidis and Turicella otitidis.

Authors:  Rachael Lappan; Sarra E Jamieson; Christopher S Peacock
Journal:  Front Cell Infect Microbiol       Date:  2020-02-14       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.